Fig. 3
From: Expanding anti-CD38 immunotherapy for lymphoid malignancies
Potent effector function of CD38-CAR T cells against WM and MCL in vivo. A Schematic of CAR T-cell treatment protocol. NSG mice were intravenously injected with 8 × 105 fLuc-transduced MCL cells (JeKo-1). After 7 days, the mice were treated with 5 × 106 CD38-CAR T cells or non-transduced T cells (control T cells), or remained untreated (n = 5 or 4). B A serial of bioluminescent imaging results showing lymphoma progression/regression in mice. C Kinetics of lymphoma progression, measured by bioluminescent imaging, in mice treated with CD38-CAR T cells, control T cells, or untreated. D Survival curve for each experimental group. E A serial of representative bioluminescent results showing WM tumor progression/regression in mice. F Kinetics of tumor progression, measured by bioluminescent imaging, in mice treated with CD38-CAR T cells, control T cells, or remained untreated. G Survival curve for each experimental group